share_log

Clarivate (NYSE:CLVT) Given New $14.00 Price Target at Morgan Stanley

Clarivate (NYSE:CLVT) Given New $14.00 Price Target at Morgan Stanley

Clarivate(紐約證券交易所股票代碼:CLVT)給予摩根士丹利14.00美元的新目標價
Financial News Live ·  2022/10/01 03:52

Clarivate (NYSE:CLVT – Get Rating) had its target price lowered by Morgan Stanley from $15.00 to $14.00 in a research report report published on Tuesday, Marketbeat reports. The firm currently has an overweight rating on the stock.

據市場報道,在週二發佈的一份研究報告中,摩根士丹利將Clarivate(紐約證券交易所代碼:CLVT-GET評級)的目標價從15.00美元下調至14.00美元。該公司目前對該股的評級為增持。

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company initiated coverage on shares of Clarivate in a report on Tuesday, July 12th. They issued an overweight rating and a $20.00 price target for the company. Royal Bank of Canada cut their price target on shares of Clarivate from $23.00 to $18.00 and set an outperform rating for the company in a report on Friday, July 1st. Finally, TheStreet raised shares of Clarivate from a d+ rating to a c rating in a report on Tuesday, May 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $16.50.

其他股票研究分析師最近也發佈了有關該股的報告。富國銀行在7月12日星期二的一份報告中啟動了對Clarivate股票的報道。他們為該公司發佈了增持評級和20.00美元的目標價。加拿大皇家銀行在7月1日星期五的一份報告中將Clarivate的股票目標價從23.00美元下調至18.00美元,併為該公司設定了表現優於大盤的評級。最後,華爾街在5月31日星期二的一份報告中將Clarivate的股票評級從d+上調至c。兩名研究分析師對該股的評級為持有,四名分析師對該公司股票的評級為買入。根據MarketBeat.com的數據,該股目前的平均評級為中等買入,平均目標價為16.50美元。

Get
到達
Clarivate
克拉裏弗
alerts:
警報:

Clarivate Stock Performance

明晰股票表現

Shares of CLVT opened at $9.39 on Tuesday. The firm has a 50-day moving average price of $12.24 and a 200 day moving average price of $14.01. The firm has a market capitalization of $6.32 billion, a PE ratio of -46.95 and a beta of 0.89. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 0.56. Clarivate has a 52-week low of $9.06 and a 52-week high of $25.63.

週二,CLVT的股價開盤報9.39美元。該公司的50日移動均線價格為12.24美元,200日移動均線價格為14.01美元。該公司市值為63.2億美元,市盈率為-46.95,貝塔係數為0.89。該公司的速動比率為0.82,流動比率為0.82,債務權益比為0.56。Clarivate的52周低點為9.06美元,52周高位為25.63美元。

Clarivate (NYSE:CLVT – Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.02. Clarivate had a net margin of 1.87% and a return on equity of 5.47%. The firm had revenue of $686.60 million during the quarter, compared to analyst estimates of $691.51 million. On average, sell-side analysts anticipate that Clarivate will post 0.7 earnings per share for the current fiscal year.
Clarivate(紐約證券交易所代碼:CLVT-GET Rating)最近一次公佈收益結果是在8月9日星期二。該公司公佈本季度每股收益(EPS)為0.19美元,比分析師普遍預期的0.17美元高出0.02美元。Clarivate的淨利潤率為1.87%,股本回報率為5.47%。該公司本季度營收為6.866億美元,而分析師預期為6.9151億美元。賣方分析師平均預計,Clarivate本財年每股收益將為0.7%。

Insider Buying and Selling at Clarivate

Clarivate的內部買入和賣出

In related news, Director Andrew Miles Snyder purchased 208,333 shares of Clarivate stock in a transaction dated Wednesday, September 14th. The stock was acquired at an average cost of $11.61 per share, with a total value of $2,418,746.13. Following the completion of the transaction, the director now directly owns 208,333 shares of the company's stock, valued at $2,418,746.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 24.88% of the company's stock.

在相關新聞中,董事安德魯·邁爾斯·斯奈德在一筆日期為9月14日(星期三)的交易中購買了208,333股Clarivate股票。收購該股票的平均成本為每股11.61美元,總價值為2,418,746.13美元。交易完成後,董事現在直接持有該公司208,333股股票,價值2,418,746.13美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以通過美國證券交易委員會網站。內部人士持有該公司24.88%的股份。

Institutional Trading of Clarivate

Clarivate的機構交易

Hedge funds have recently made changes to their positions in the stock. Swiss National Bank increased its holdings in Clarivate by 13.9% in the first quarter. Swiss National Bank now owns 1,524,100 shares of the company's stock worth $25,544,000 after buying an additional 186,400 shares during the last quarter. Toronto Dominion Bank increased its holdings in Clarivate by 8.6% in the first quarter. Toronto Dominion Bank now owns 75,353 shares of the company's stock worth $1,263,000 after buying an additional 5,945 shares during the last quarter. Diversified Trust Co increased its holdings in Clarivate by 10.4% in the first quarter. Diversified Trust Co now owns 37,820 shares of the company's stock worth $634,000 after buying an additional 3,575 shares during the last quarter. TownSquare Capital LLC acquired a new position in Clarivate in the first quarter worth approximately $349,000. Finally, Robeco Institutional Asset Management B.V. acquired a new position in Clarivate in the first quarter worth approximately $154,000. 83.42% of the stock is owned by hedge funds and other institutional investors.

對衝基金最近對其股票頭寸進行了調整。瑞士國家銀行第一季度增持Clarivate股份13.9%。瑞士國家銀行現在持有1,524,100股該公司股票,價值25,544,000美元,上個季度又購買了186,400股。多倫多道明銀行第一季度增持Clarivate 8.6%。多倫多道明銀行現在持有該公司75,353股股票,價值1,263,000美元,上個季度又購買了5,945股。多元化信託公司在第一季度增持了10.4%的Clarivate。多元化信託公司目前持有37,820股該公司股票,價值634,000美元,此前該公司在上個季度又購買了3,575股。Townsquare Capital LLC在第一季度收購了Clarivate的一個新頭寸,價值約349,000美元。最後,Robeco Institution Asset Management B.V.在第一季度收購了Clarivate的一個新頭寸,價值約15.4萬美元。83.42%的股票由對衝基金和其他機構投資者持有。

Clarivate Company Profile

創建公司簡介

(Get Rating)

(獲取評級)

Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs.

Clarivate Plc是一家信息服務和分析公司,為科學研究、創新和品牌的發現、保護和商業化提供結構化信息和分析。它向計劃、資助、實施和利用研究的組織提供科學網產品和服務,如科學網、INCITES、期刊引文報告、EndNote、ScholarOne、Converis、Publons和Kopnio;為製藥和生物技術公司提供生命科學產品,包括Corellis和Newport Integrity,以支持與新藥開發和商業化相關的研究、市場情報和競爭監測。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Clarivate (CLVT)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Thor Industries Hammers Out A Bottom
  • How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
  • 免費獲取StockNews.com關於Clarivate的研究報告(CLVT)
  • 電動汽車電池製造商Freyr將在全球大舉擴張
  • MarketBeat:回顧一週9/26-9/30
  • 這是買入美光科技的難忘時刻
  • 雷神工業走出谷底
  • Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何?

Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.

接受Clarivate Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Clarivate和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論